comparemela.com

நோய் மையங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

US promotes serial testing for COVID-19 with streamlined approval

US promotes serial testing for COVID-19 with streamlined approval ANI | Updated: Mar 17, 2021 08:30 IST Washington [US], March 17 (ANI/Sputnik): The US government issued simplified rules for developers of coronavirus tests to promote serial screening, a process in which the same individual is tested multiple times within a few days, the Food and Drug Administration (FDA) said. Today, we are providing information for test developers about a streamlined path to emergency use authorization, the FDA said in a press release on Tuesday. This [path] applies to developers of molecular and antigen tests, for use in serial testing programs, as well as at-home tests for use in a serial manner outside of a testing program.

University of Kentucky researchers link low blood amylin level to reduced progression of Alzheimer s

 E-Mail IMAGE: Nirmal Verma, Ph.D., and several other researchers contributed to the recent study potentially linking low blood amylin levels to reduced progression of Alzheimer s disease. view more  Credit: Photo by Pete Comparoni | UKphoto LEXINGTON, Ky. (January 20, 2021) - More than 5.7 million Americans live with Alzheimer s disease and that number is projected to triple by 2050. Despite the growing number there is not a cure. Florin Despa a professor with the University of Kentucky s department of pharmacology and nutritional sciences says, The mechanisms underlying neurodegenerative diseases are largely unknown and effective therapies are lacking. That is why numerous studies and trials are ongoing around the world including at the University of Kentucky. One of those studies by University of Kentucky researchers was recently published in

UK Study Potentially Links Low Blood Amylin Level to Reduced Progression of Alzheimer s Disease

The team’s work shows that early pathological processes in the brains of individuals who are genetically predisposed to develop Alzheimer’s disease are modulated by a pancreatic hormone called amylin. This study is the first to show that the brains of patients with familial AD accumulate amyloid-forming amylin secreted by the pancreas. “Our study suggests an alternative approach to reduce the progression of Alzheimer’s disease through the modulation of blood levels of amylin. In addition, the results of this study can point to the pancreatic hormone amylin as a potential missing molecular link between metabolic disorders and increased risk for Alzheimer’s disease. Specifically, amylin dysregulation contributes to both type-2 diabetes and Alzheimer’s disease.”

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.